The Florida Senate Committee on Health Policy approved a bill that would require pharmacists to notify physicians when they substitute a biosimilar drug for a brand-name biologic drug. The requirement would apply for five years after the FDA's approval of a biosimilar as an interchangeable substitute for a brand-name biologic.

Full Story:
Drug Store News

Related Summaries